Patient-Centered Practical Vaccine Talk For Busy Clinicians
Part of paid clinical trials in Worcester, Massachusetts.
- Sponsor
- University of Massachusetts, Worcester
- Study ID
- NCT07651761
- Status
- Recruiting
Conditions
- COVID-19
- Influenza
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Provider communication training — OTHERProviders in participating intervention clinics will complete an educational program (PCP-VAX) on strategies for communicating with patients about the influenza and COVID-19 vaccines.
Study Details
The goal of this study is to assess the effect of an educational intervention for primary care providers (PCPs) on influenza and COVID-19 vaccine uptake among their adult patients through a pragmatic, cluster randomized trial in primary care clinics.
Key Dates
- Start date
- Jul 15, 2026
- Status verified
- Jun 2026
- Primary completion
- May 15, 2028
- Completion
- May 15, 2028
Study Design
- Enrollment
- 24,500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Other: Intervention ArmProvider educational intervention.
- No Intervention: Control ArmUsual care
Primary Outcome Measure
Receipt of 2026/2027 influenza vaccine [ Time Frame: Within one month of the end of the study period ]
Central Contacts
- Kimberly A Fisher, MD(508) 334-1975
- Cassie L Saphirak, MA508-856-3493
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UMass Chan Medical School | Worcester | Massachusetts | 01602 |
Find similar trials in Worcester, MA
By condition
By specialty
By research site
Related Studies
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
- Positron Emission Tomography (PET) Imaging of ThrombosisPHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseasePHASE3 · Recruiting · Pfizer · Phoenix, Arizona
- Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in IndiaRecruiting · Boston University · Boston, Massachusetts